Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719451 | 0.88 | DRD4 (0.56) | DRD4LMNAMAPTTSHRGAA | |
| SCHEMBL716624 | 0.81 | GAA (0.47) | DRD4MAPTTSHRGAAHSD17B10 | |
| SCHEMBL710529 | 0.81 | ADORA2A (0.45) | LMNAMAPTTSHRGAAALDH1A1 | |
| SCHEMBL712030 | 0.80 | DRD4 (0.57) | DRD4MAPTHTR1AKDM4EALDH1A1 | |
| SCHEMBL719983 | 0.79 | L3MBTL1 (0.54) | DRD4MAPTTSHRGAAHSD17B10 | |
| SCHEMBL713856 | 0.79 | HTT (0.52) | MAPTGAAHSD17B10KDM4EALDH1A1 | |
| SCHEMBL713735 | 0.79 | HTT (0.52) | MAPTGAAHSD17B10KDM4EALDH1A1 | |
| SCHEMBL714240 | 0.78 | TERT (0.51) | DRD4MAPTGAAKDM4EALDH1A1 | |
| SCHEMBL709933 | 0.78 | DRD4 (0.59) | DRD4MAPTTSHRGAAKDM4E | |
| SCHEMBL712167 | 0.78 | DRD4 (0.59) | DRD4MAPTHSD17B10HTR1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | claimed |
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | disclosed |
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | disclosed |
| US-8124637-B2 | Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-02-28 | — | — | US | disclosed |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207719-A1 | Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof | TERT, ACIN1, AK2 | DRD4 4382/4885LMNA 543/4885MAPT 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.